Market Overview

UPDATE: Citigroup Reiterates Medtronic at Buy Following Kanghui Holdings Deal

Share:
Related MDT
Mid-Afternoon Market Update: Dow Drops 125 Points; Cliffs Natural Resources Shares Spike Higher
Mid-Day Market Update: Dow Falls Over 50 Points; Celator Pharmaceuticals Shares Jump After Acquisition Announcement By Jazz Pharmaceuticals
Medtronic's (MDT) CEO Omar Ishrak on Q4 2016 Results - Earnings Call Transcript (Seeking Alpha)

Citigroup maintained its Buy rating on Medtronic (NYSE: MDT) as the company announced the acquisition of Kanghui Holdings (NYSE: KH), thus likely ending its current joint venture with Chinese firm Weigao.

Citigroup noted, "KH is expected to generate $65MM in annual sales in 2012 with growth in excess of 20%. Trauma is 60% of sales and spine is around 33%. The sales level is similar to MDT's current run rate of sales from the Weigao JV but has a higher trauma and lower recon mix. MDT has an option to acquire Weigao's 49% stake in the JV by May 2013 for a range of $450-725MM or the JV would expire in January 2014. Since MDT paid more for KH, we assume either the management fit and/or product mix are considered preferable."

Medtronic closed at $43.48 on Thursday.

Latest Ratings for MDT

DateFirmActionFromTo
Apr 2016SunTrust Robinson HumphreyInitiates Coverage onBuy
Mar 2016NomuraInitiates Coverage onBuy
Mar 2016Morgan StanleyMaintainsOverweight

View More Analyst Ratings for MDT
View the Latest Analyst Ratings

Posted-In: CitigroupAnalyst Color News Reiteration M&A Intraday Update Analyst Ratings

 

Related Articles (MDT + KH)

View Comments and Join the Discussion!